Skip to main content

Table 1 Clinical and pathological characteristics of patients

From: Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells

CLDN1 expression

< median

> median

total

p-value***

(n = 29)

(n = 29)

(n = 58)

N

(%)

N

(%)

N

(%)

Gender

       

 Male

22

(75.9)

13

(44.8)

35

(60.3)

0.03

 Female

7

(24.1)

16

(55.2)

23

(39.7)

 

Age (years), median [63]

       

 ≤ 63

11

(38.0)

18

(62.1)

29

(50.0)

0.07

 > 63

18

(62.0)

11

(37.9)

29

(50.0)

 

Primary tumor localization

       

 Right colon

8

(27.6)

12

(41.4)

20

(34.5)

0.31

 Left colon

20

(68.9)

17

(58.6)

37

(63.8)

 

 Missing data

1

(3.4)

0

(0.0)

1

(1.7)

 

Differentiation

       

 Well

10

(34.5)

8

(27.6)

18

(31.0)

0.38

 Moderate

15

(51.7)

20

(69.0)

35

(60.3)

 

 Missing data

4

(13.8)

1

(3.4)

5

(8.7)

 

Synchronous

17

(58.6)

24

(82.7)

41

(70.7)

0.08

Metachronous

12

(41.4)

5

(17.3)

17

(29.3)

 

Chemotherapy regimen

       

 FOLFIRI

5

(17.3)

8

(27.6)

13

(22.4)

0.58

 FOLFOX

13

(44.8)

10

(34.5)

23

(39.7)

 

 FOLFIRINOX

11

(37.9)

11

(37.9)

22

(37.9)

 

Targeted therapy

       

 YES

6

(20.7)

11

(37.9)

17

(29.3)

0.15

 NO

23

(79.3)

18

(62.1)

41

(70.7)

 

Number of cures,

       

 ≤ 6

17

(58.6)

19

(65.5)

28

(48.3)

0.56

 > 6

11

(37.9)

9

(31.0)

28

(48.3)

 

 Missing data

1

(3.5)

1

(3.5)

2

(3.4)

 

KRAS status

       

 WT

7

(24.1)

10

(34.5)

17

(29.3)

0.74

 Mutated

12

(41.4)

14

(48.3)

26

(44.8)

 

 Missing data

10

(34.5)

5

(17.2)

15

(25.9)

 

Histological response

       

Blazer score*

       

 1

18

(62.0)

9

(31.0)

27

(46.6)

0.029

 2

10

(34.5)

17

(58.6)

27

(46.6)

 

Missing data

1

(3.5)

3

(10.4

4

(6.8)

 

TRG**

       

 2

6

(20.7)

1

(3.5)

7

(12.0)

0.017

 3

12

(41.3)

5

(17.2)

17

(29.3)

 

 4

10

(34.5)

19

(65.5)

29

(50.0)

 

 5

0

(0.0)

1

(3.5)

1

(1.7)

 

Missing data

1

(3.5)

3

(10.3)

4

(7.0)

 
  1. * Blazer score (1 = major response: 1–49% of residual cancer cells; and 2 = minor response: ≥50% of residual cancer cells).**TRG = scoring system based on the presence of residual tumor cells and fibrosis extent.*** Chi-square or Fisher’s exact test